Adverse events following immunisation with a meningococcal serogroup B vaccine: report from post-marketing surveillance, Germany, 2013 to 2016

In January 2013, a novel vaccine against Neisseria meningitidis serogroup B, the multicomponent meningococcal serogroup B vaccine (4CMenB), was approved by the European Medicines Agency. We aimed to evaluate the safety profile of this vaccine. Methods: All adverse events following immunisation (AEFI...

Descripción completa

Detalles Bibliográficos
Autores principales: Mentzer, Dirk, Oberle, Doris, Keller-Stanislawski, Brigitte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5930728/
https://www.ncbi.nlm.nih.gov/pubmed/29717697
http://dx.doi.org/10.2807/1560-7917.ES.2018.23.17.17-00468

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5930728/
https://www.ncbi.nlm.nih.gov/pubmed/29717697
http://dx.doi.org/10.2807/1560-7917.ES.2018.23.17.17-00468

Ejemplares similares